Biggest News Aggregation in the World
📰 Limitations Associated News

Page 2 - Limitations Associated News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Limitations Associated. Real-time updates on events, politics, business and more.

Surgalign Holdings, Inc. Announces First Quarter 2022 Results and Raises Full Year 2022 Revenue Guidance Range

10.05.2022 - DEERFIELD, Ill., May 10, 2022 (GLOBE NEWSWIRE) - Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced financial results ...
United States San Diego Baden Wüberg Mike Vallie Mario Brkaric Copies Of The Company

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Stem Cell Manufacturing Market by Product, Application, End-user and Region

The "Global Stem Cell Manufacturing Market by Product (Consumables, Instrument, HSCs, MSCs, iPSCs, ESCs), Application (Research, Clinical (Autologous, Allogenic), Cell & Tissue Banking), End-user (Pharma & Biotech, Hospitals, Tissue Bank), and Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
United States Miltenyi Biotec Gmb Asia Pacific Merck Millipore Cellgenix Gmb Laura Wood
Source: yahoo.com

Surgalign Holdings, Inc. Announces First Quarter 2021 Results

Message : Required fields DEERFIELD, Ill., May 10, 2021 (GLOBE NEWSWIRE) -- Surgalign Spine Technologies, (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today reported operating results for the first quarter of 2021. Highlights: Total global spine revenue of $23.3 million, compared to $27.1 million in the first quarter of 2020 Net loss from continuing operations of $15.2 million inclusive of approximate...
San Diego United States Baden Wüberg Marc Mackey Surgalign Holdings Holo Surgical Inc

Orthofix Reports First Quarter 2021 Results

  Gross profit decreased $1.7 million to $79.7 million. Gross margin decreased to 75.5% compared to 77.7% in the prior year period. Net loss was $(5.8) million, or $(0.30) per share, compared to net income of $25.7 million, or $1.32 per share in the prior year period. Adjusted net income was $3.4 million, or $0.17 per share, compared to adjusted net income of $1.7 million, or $0.09 per share in the prior year period. EBITDA was $1.8 million, compared to $12.4 million in the prior year period. ...
United States Jon Serbousek Drug Administration University Of Modena Orthofix Inc Exchange Commission

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science